Abstracts tagged "anti-TNF therapy and remission"

Abstract Number: 2906 • 2019 ACR/ARP Annual Meeting
DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial
Elise van Mulligen¹, Angelique Weel ², Martijn Kuijper ², Mieke Hazes ¹, Annette van der Helm-van Mil ³ and Pascal de Jong ¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: In rheumatoid arthritis (RA) disease outcomes have improved enormously in the last decades. Due to early initiation of therapy, a treat-to-target approach and a…
Abstract Number: 2744 • 2017 ACR/ARHP Annual Meeting
Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-TNF Treatment
Petros P Sfikakis¹, Aikaterini Arida¹, Stylianos Panopoulos², Kalliopi Fragkiadaki², George Pentazos³, Katerina Laskari³, Maria Tektonidou¹ and Nikos Markomichelakis², ¹First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, athens, Greece, ²First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece, ³Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece
Background/Purpose: Anti-TNF treatment has been shown to be effective in inducing complete remission in many Behcet’s disease (BD) patients with eye, large vessel, intestine and…
Abstract Number: 608 • 2016 ACR/ARHP Annual Meeting
Initial Intensive Therapy of Adalimumab and Methotrexate Is Associated with Long-Term Structural Remission and Low Disease Activity after Adalimumab Discontinuation Is Maintained up to 3 Years in Japanese Patients: Hopeful-3 Study
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Naoki Agata⁵ and Tsutomu Takeuchi⁶, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Tokyo Women's Medical University, Tokyo, Japan, ³Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie GK, Tokyo, Japan, ⁶Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Methods: Of 172 patients enrolled, 135 (ADA continuation, n=61; ADA discontinuation, n=74) with DAS28–CRP at both week 52 (start of HOPEFUL-2) and week 208…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].